Bukwang Pharm - Asset Resilience Ratio
Bukwang Pharm (003000) has an Asset Resilience Ratio of 39.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Bukwang Pharm's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how Bukwang Pharm's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Bukwang Pharm to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Bukwang Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 003000 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩188.03 Billion | 39.75% |
| Total Liquid Assets | ₩188.03 Billion | 39.75% |
Asset Resilience Insights
- Very High Liquidity: Bukwang Pharm maintains exceptional liquid asset reserves at 39.75% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Bukwang Pharm Industry Peers by Asset Resilience Ratio
Compare Bukwang Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Bukwang Pharm (2007–2024)
The table below shows the annual Asset Resilience Ratio data for Bukwang Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 10.72% | ₩40.00 Billion ≈ $27.11 Million |
₩373.18 Billion ≈ $252.90 Million |
+10.34pp |
| 2021-12-31 | 0.38% | ₩1.50 Billion ≈ $1.02 Million |
₩397.42 Billion ≈ $269.32 Million |
-2.19pp |
| 2020-12-31 | 2.57% | ₩10.30 Billion ≈ $6.98 Million |
₩400.97 Billion ≈ $271.73 Million |
-3.95pp |
| 2014-12-31 | 6.51% | ₩15.43 Billion ≈ $10.46 Million |
₩236.82 Billion ≈ $160.49 Million |
-2.28pp |
| 2013-12-31 | 8.79% | ₩20.07 Billion ≈ $13.60 Million |
₩228.21 Billion ≈ $154.66 Million |
+3.73pp |
| 2008-12-31 | 5.06% | ₩11.67 Billion ≈ $7.91 Million |
₩230.55 Billion ≈ $156.24 Million |
-8.07pp |
| 2007-12-31 | 13.13% | ₩28.24 Billion ≈ $19.14 Million |
₩215.02 Billion ≈ $145.71 Million |
-- |
About Bukwang Pharm
Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, live… Read more